Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia
B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 1...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2019-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_6bcd553065a1432b82eb3d0e9af75eb9 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Suliman A. Alsagaby |e author |
| 245 | 0 | 0 | |a Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia |
| 260 | |b Frontiers Media S.A., |c 2019-09-01T00:00:00Z. | ||
| 500 | |a 10.4081/oncol.2019.435 | ||
| 500 | |a 1970-5557 | ||
| 500 | |a 1970-5565 | ||
| 520 | |a B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of cancer seen in children and is characterized by a variable clinical course. Although there have been remarkable improvements in the therapy outcomes of pediatric B-ALL, treatment failure remains the leading-cause of death in 18% of the afflicted patients during the first 5 years after diagnosis. Molecular heterogeneities of pediatric B-ALL play important roles as determinants of the therapy response. Therefore, many of these molecular abnormalities have an established prognostic value in the disease. The present review discusses the omics-based revelations from epigenomics, genomics, transcriptomics and proteomics about treatment failure in pediatric B-ALL. Next it highlights the promise of the molecular aberration-targeted therapy to improve the treatment outcomes. | ||
| 546 | |a EN | ||
| 690 | |a Pediatric B-ALL | ||
| 690 | |a therapy failure | ||
| 690 | |a omics. | ||
| 690 | |a Other systems of medicine | ||
| 690 | |a RZ201-999 | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Oncology Reviews, Vol 13, Iss 2 (2019) | |
| 787 | 0 | |n https://oncologyreviews.org/index.php/or/article/view/435 | |
| 787 | 0 | |n https://doaj.org/toc/1970-5557 | |
| 787 | 0 | |n https://doaj.org/toc/1970-5565 | |
| 856 | 4 | 1 | |u https://doaj.org/article/6bcd553065a1432b82eb3d0e9af75eb9 |z Connect to this object online. |